Results 241 to 250 of about 2,638,873 (305)

TRAIL‐PEG‐Apt‐PLGA nanosystem as an aptamer‐targeted drug delivery system potential for triple‐negative breast cancer therapy using in vivo mouse model

open access: yesMolecular Oncology, EarlyView.
Aptamers are used both therapeutically and as targeting agents in cancer treatment. We developed an aptamer‐targeted PLGA–TRAIL nanosystem that exhibited superior therapeutic efficacy in NOD/SCID breast cancer models. This nanosystem represents a novel biotechnological drug candidate for suppressing resistance development in breast cancer.
Gulen Melike Demirbolat   +8 more
wiley   +1 more source

The PI3Kδ inhibitor roginolisib (IOA‐244) preserves T‐cell function and activity

open access: yesMolecular Oncology, EarlyView.
Identification of novel PI3K inhibitors with limited immune‐related adverse effects is highly sought after. We found that roginolisib and idelalisib inhibit chronic lymphocytic leukemia (CLL) cells and Treg suppressive functions to similar extents, but roginolisib affects cytotoxic T‐cell function and promotion of pro‐inflammatory T helper subsets to a
Elise Solli   +7 more
wiley   +1 more source

Navigating care together: developing a collaborative checklist to improve care for children with intellectual disabilities. [PDF]

open access: yesRes Involv Engagem
Trower HL   +11 more
europepmc   +1 more source

Adherence to handwashing behaviour and its impact on the incidence and death of viral respiratory infectious diseases: a systematic review, meta-analysis and modelling study. [PDF]

open access: yesBMJ Glob Health
Zhou W   +15 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy